Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Schrodinger, Inc. - Common Stock (NQ:SDGR)

21.42 -0.29 (-1.34%)
Streaming Delayed Price Updated: 12:18 PM EDT, Jul 11, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 310,195
Open 21.42
Bid (Size) 21.39 (3)
Ask (Size) 21.45 (1)
Prev. Close 21.71
Today's Range 21.05 - 21.51
52wk Range 16.60 - 28.47
Shares Outstanding 62,027,061
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Schrödinger, Inc. - SDGR
From Pomerantz LLP
Via GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Schrödinger, Inc. - SDGR
From Pomerantz LLP
Via GlobeNewswire

Performance

YTD
+5.0%
+5.0%
1 Month
-18.0%
-18.0%
3 Month
+11.4%
+11.4%
6 Month
+11.0%
+11.0%
1 Year
+4.1%
+4.1%

More News

Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Schrödinger, Inc. - SDGR
Via ACCESS Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Schrödinger, Inc. - SDGR
From Pomerantz LLP
Via GlobeNewswire
Schrödinger Receives Fast Track Designation for SGR-1505 for the Treatment of Relapsed/Refractory Waldenström Macroglobulinemia
From Schrödinger
Via Business Wire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Schrödinger, Inc. - SDGR
Via ACCESS Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Schrödinger, Inc. - SDGR
Via ACCESS Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Schrödinger, Inc. - SDGR
Via ACCESS Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Schrödinger, Inc. - SDGR
From Pomerantz LLP
Via GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Schrödinger, Inc. - SDGR
Via ACCESS Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Schrödinger, Inc. - SDGR
From Pomerantz LLP
Via GlobeNewswire
Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From Schrödinger
Via Business Wire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Schrödinger, Inc. - SDGR
From Pomerantz LLP
Via GlobeNewswire
Schrödinger Reports Encouraging Initial Phase 1 Clinical Data for SGR-1505 at EHA Annual Congress
From Schrödinger
Via Business Wire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Schrödinger, Inc. - SDGR
From Pomerantz LLP
Via GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Schrödinger, Inc. - SDGR
From Pomerantz LLP
Via GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Schrödinger, Inc. - SDGR
From Pomerantz LLP
Via GlobeNewswire
Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Commercial Officer
From Schrödinger
Via Business Wire
Schrödinger Expands Executive Leadership Team with Appointment of Mannix Aklian as Chief Commercial Officer, Global Head of Software Sales and Marketing
From Schrödinger
Via Business Wire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Schrödinger, Inc. - SDGR
From Pomerantz LLP
Via GlobeNewswire
Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From Schrödinger
Via Business Wire
Schrödinger to Present at Jefferies Global Healthcare Conference
From Schrödinger
Via Business Wire
Schrödinger Announces CFO Appointment
From Schrödinger
Via Business Wire
Schrödinger to Present Phase 1 Clinical Data on MALT1 Inhibitor SGR-1505 at EHA Annual Congress and International Conference on Malignant Lymphoma
From Schrödinger
Via Business Wire
Schrödinger Reports Strong First Quarter 2025 Financial Results
From Schrödinger
Via Business Wire

Frequently Asked Questions

Is Schrodinger, Inc. - Common Stock publicly traded?
Yes, Schrodinger, Inc. - Common Stock is publicly traded.
What exchange does Schrodinger, Inc. - Common Stock trade on?
Schrodinger, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Schrodinger, Inc. - Common Stock?
The ticker symbol for Schrodinger, Inc. - Common Stock is SDGR on the Nasdaq Stock Market
What is the current price of Schrodinger, Inc. - Common Stock?
The current price of Schrodinger, Inc. - Common Stock is 21.42
When was Schrodinger, Inc. - Common Stock last traded?
The last trade of Schrodinger, Inc. - Common Stock was at 07/11/25 12:18 PM ET
What is the market capitalization of Schrodinger, Inc. - Common Stock?
The market capitalization of Schrodinger, Inc. - Common Stock is 1.33B
How many shares of Schrodinger, Inc. - Common Stock are outstanding?
Schrodinger, Inc. - Common Stock has 1B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.